“2025 marked our transition in expanding AI Nose’s commercial focus from healthcare into industrial markets. Our focus in 2025 was building the platform and partnerships required for scale,” said Eddy Tsai, Chairman and CEO of Ainos (AIMD). “As we enter 2026, that groundwork is translating into operational momentum, with early AI Nose deployments underway, particularly in semiconductor environments. As deployments expand, AI Nose generates Smell ID data that continuously trains our SLM, reinforcing our long-term data advantage.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIMD:
- Ainos says WSJ highlights emerging ‘Smell AI’ in article
- Ainos announces continued validation testing of AI Nose platform
- Ainos CEO says AI Nose platform transitioning into industrial deployment
- Ainos activates industrial deployment roadmap of up to 20,000 units
- Ainos announces interim results from VELDONA clinical trial